nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0329	0.0982	CcSEcCtD
Atomoxetine—Sinus headache—Metformin—polycystic ovary syndrome	0.0264	0.0787	CcSEcCtD
Atomoxetine—Sinus congestion—Metformin—polycystic ovary syndrome	0.0173	0.0515	CcSEcCtD
Atomoxetine—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.0163	0.0488	CcSEcCtD
Atomoxetine—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.0146	0.0436	CcSEcCtD
Atomoxetine—Upset stomach—Metformin—polycystic ovary syndrome	0.0131	0.0391	CcSEcCtD
Atomoxetine—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0106	0.0317	CcSEcCtD
Atomoxetine—CYP2C19—urine—polycystic ovary syndrome	0.0106	0.114	CbGeAlD
Atomoxetine—Rigors—Metformin—polycystic ovary syndrome	0.0105	0.0314	CcSEcCtD
Atomoxetine—NPY1R—adrenal cortex—polycystic ovary syndrome	0.0088	0.0945	CbGeAlD
Atomoxetine—NPY1R—pituitary gland—polycystic ovary syndrome	0.00711	0.0764	CbGeAlD
Atomoxetine—NPY1R—adipose tissue—polycystic ovary syndrome	0.00708	0.076	CbGeAlD
Atomoxetine—Nasal congestion—Metformin—polycystic ovary syndrome	0.00685	0.0204	CcSEcCtD
Atomoxetine—HTR2A—urine—polycystic ovary syndrome	0.00677	0.0728	CbGeAlD
Atomoxetine—Lethargy—Metformin—polycystic ovary syndrome	0.00637	0.019	CcSEcCtD
Atomoxetine—NPY1R—adrenal gland—polycystic ovary syndrome	0.00635	0.0682	CbGeAlD
Atomoxetine—CYP3A4—urine—polycystic ovary syndrome	0.00627	0.0674	CbGeAlD
Atomoxetine—CYP2D6—urine—polycystic ovary syndrome	0.00617	0.0663	CbGeAlD
Atomoxetine—NPY1R—vagina—polycystic ovary syndrome	0.00588	0.0632	CbGeAlD
Atomoxetine—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.0057	0.017	CcSEcCtD
Atomoxetine—Breast disorder—Metformin—polycystic ovary syndrome	0.00564	0.0168	CcSEcCtD
Atomoxetine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00558	0.0166	CcSEcCtD
Atomoxetine—NPY1R—endocrine gland—polycystic ovary syndrome	0.00551	0.0591	CbGeAlD
Atomoxetine—Influenza—Metformin—polycystic ovary syndrome	0.00539	0.0161	CcSEcCtD
Atomoxetine—Sweating increased—Metformin—polycystic ovary syndrome	0.00525	0.0157	CcSEcCtD
Atomoxetine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00517	0.0154	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00501	0.015	CcSEcCtD
Atomoxetine—Infestation NOS—Metformin—polycystic ovary syndrome	0.00481	0.0143	CcSEcCtD
Atomoxetine—Infestation—Metformin—polycystic ovary syndrome	0.00481	0.0143	CcSEcCtD
Atomoxetine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00429	0.0128	CcSEcCtD
Atomoxetine—Flushing—Metformin—polycystic ovary syndrome	0.00401	0.012	CcSEcCtD
Atomoxetine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00401	0.012	CcSEcCtD
Atomoxetine—Angiopathy—Metformin—polycystic ovary syndrome	0.00392	0.0117	CcSEcCtD
Atomoxetine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00389	0.0116	CcSEcCtD
Atomoxetine—Chills—Metformin—polycystic ovary syndrome	0.00387	0.0116	CcSEcCtD
Atomoxetine—Malnutrition—Metformin—polycystic ovary syndrome	0.00376	0.0112	CcSEcCtD
Atomoxetine—Flatulence—Metformin—polycystic ovary syndrome	0.0037	0.011	CcSEcCtD
Atomoxetine—Dysgeusia—Metformin—polycystic ovary syndrome	0.00368	0.011	CcSEcCtD
Atomoxetine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00361	0.0108	CcSEcCtD
Atomoxetine—Vision blurred—Metformin—polycystic ovary syndrome	0.00354	0.0106	CcSEcCtD
Atomoxetine—Tremor—Metformin—polycystic ovary syndrome	0.00352	0.0105	CcSEcCtD
Atomoxetine—Syncope—Metformin—polycystic ovary syndrome	0.00337	0.0101	CcSEcCtD
Atomoxetine—Palpitations—Metformin—polycystic ovary syndrome	0.00332	0.00991	CcSEcCtD
Atomoxetine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.0033	0.00985	CcSEcCtD
Atomoxetine—Chest pain—Metformin—polycystic ovary syndrome	0.0032	0.00954	CcSEcCtD
Atomoxetine—Myalgia—Metformin—polycystic ovary syndrome	0.0032	0.00954	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00318	0.00948	CcSEcCtD
Atomoxetine—Infection—Metformin—polycystic ovary syndrome	0.00305	0.00909	CcSEcCtD
Atomoxetine—Shock—Metformin—polycystic ovary syndrome	0.00302	0.009	CcSEcCtD
Atomoxetine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00301	0.00897	CcSEcCtD
Atomoxetine—Skin disorder—Metformin—polycystic ovary syndrome	0.00298	0.00889	CcSEcCtD
Atomoxetine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00296	0.00884	CcSEcCtD
Atomoxetine—Anorexia—Metformin—polycystic ovary syndrome	0.00292	0.00872	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00279	0.00834	CcSEcCtD
Atomoxetine—Paraesthesia—Metformin—polycystic ovary syndrome	0.00275	0.00822	CcSEcCtD
Atomoxetine—Somnolence—Metformin—polycystic ovary syndrome	0.00273	0.00813	CcSEcCtD
Atomoxetine—Dyspepsia—Metformin—polycystic ovary syndrome	0.0027	0.00805	CcSEcCtD
Atomoxetine—Decreased appetite—Metformin—polycystic ovary syndrome	0.00267	0.00795	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00265	0.0079	CcSEcCtD
Atomoxetine—Fatigue—Metformin—polycystic ovary syndrome	0.00264	0.00789	CcSEcCtD
Atomoxetine—Constipation—Metformin—polycystic ovary syndrome	0.00262	0.00782	CcSEcCtD
Atomoxetine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00253	0.00754	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00251	0.00748	CcSEcCtD
Atomoxetine—Urticaria—Metformin—polycystic ovary syndrome	0.00244	0.00727	CcSEcCtD
Atomoxetine—Abdominal pain—Metformin—polycystic ovary syndrome	0.00242	0.00723	CcSEcCtD
Atomoxetine—HTR1B—endocrine gland—polycystic ovary syndrome	0.00234	0.0251	CbGeAlD
Atomoxetine—Asthenia—Metformin—polycystic ovary syndrome	0.0022	0.00656	CcSEcCtD
Atomoxetine—HTR2A—embryo—polycystic ovary syndrome	0.00219	0.0235	CbGeAlD
Atomoxetine—Pruritus—Metformin—polycystic ovary syndrome	0.00217	0.00647	CcSEcCtD
Atomoxetine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00216	0.0232	CbGeAlD
Atomoxetine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.00212	0.0228	CbGeAlD
Atomoxetine—Diarrhoea—Metformin—polycystic ovary syndrome	0.0021	0.00626	CcSEcCtD
Atomoxetine—Dizziness—Metformin—polycystic ovary syndrome	0.00203	0.00605	CcSEcCtD
Atomoxetine—Ephedrine—ADRA1A—polycystic ovary syndrome	0.00197	0.0879	CrCbGaD
Atomoxetine—Vomiting—Metformin—polycystic ovary syndrome	0.00195	0.00582	CcSEcCtD
Atomoxetine—Rash—Metformin—polycystic ovary syndrome	0.00193	0.00577	CcSEcCtD
Atomoxetine—Dermatitis—Metformin—polycystic ovary syndrome	0.00193	0.00576	CcSEcCtD
Atomoxetine—Headache—Metformin—polycystic ovary syndrome	0.00192	0.00573	CcSEcCtD
Atomoxetine—Modafinil—ADRA1B—polycystic ovary syndrome	0.0019	0.0851	CrCbGaD
Atomoxetine—CYP2C19—vagina—polycystic ovary syndrome	0.00188	0.0202	CbGeAlD
Atomoxetine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.00187	0.0201	CbGeAlD
Atomoxetine—Phenoxybenzamine—ADRA1D—polycystic ovary syndrome	0.00185	0.0826	CrCbGaD
Atomoxetine—Nausea—Metformin—polycystic ovary syndrome	0.00182	0.00543	CcSEcCtD
Atomoxetine—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00176	0.0189	CbGeAlD
Atomoxetine—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.00168	0.0749	CrCbGaD
Atomoxetine—Propranolol—ADRB3—polycystic ovary syndrome	0.00164	0.0732	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRA1B—polycystic ovary syndrome	0.00158	0.0705	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRA1A—polycystic ovary syndrome	0.00149	0.0666	CrCbGaD
Atomoxetine—HTR2A—pituitary gland—polycystic ovary syndrome	0.00145	0.0156	CbGeAlD
Atomoxetine—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.00143	0.0639	CrCbGaD
Atomoxetine—HTR2A—adrenal gland—polycystic ovary syndrome	0.0013	0.0139	CbGeAlD
Atomoxetine—HTR2A—vagina—polycystic ovary syndrome	0.0012	0.0129	CbGeAlD
Atomoxetine—Ephedrine—ADRB2—polycystic ovary syndrome	0.00117	0.0523	CrCbGaD
Atomoxetine—HTR2A—endocrine gland—polycystic ovary syndrome	0.00112	0.0121	CbGeAlD
Atomoxetine—Benzphetamine—ADRA1A—polycystic ovary syndrome	0.00111	0.0497	CrCbGaD
Atomoxetine—CYP2D6—female gonad—polycystic ovary syndrome	0.0011	0.0118	CbGeAlD
Atomoxetine—Phenoxybenzamine—ADRA1A—polycystic ovary syndrome	0.00106	0.0475	CrCbGaD
Atomoxetine—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00104	0.0112	CbGeAlD
Atomoxetine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.00102	0.011	CbGeAlD
Atomoxetine—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.000963	0.043	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRB2—polycystic ovary syndrome	0.000887	0.0396	CrCbGaD
Atomoxetine—Warfarin—CYP1A1—polycystic ovary syndrome	0.000798	0.0357	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRB2—polycystic ovary syndrome	0.000632	0.0282	CrCbGaD
Atomoxetine—Propranolol—ADRB2—polycystic ovary syndrome	0.000623	0.0278	CrCbGaD
Atomoxetine—Methadone—CYP19A1—polycystic ovary syndrome	0.000596	0.0266	CrCbGaD
Atomoxetine—Propranolol—CYP1A1—polycystic ovary syndrome	0.000534	0.0239	CrCbGaD
Atomoxetine—Desipramine—ADRB2—polycystic ovary syndrome	0.000472	0.0211	CrCbGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	7.79e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	7.74e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PGR—polycystic ovary syndrome	7.73e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SCT—polycystic ovary syndrome	7.73e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	7.63e-05	0.000139	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—polycystic ovary syndrome	7.62e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	7.53e-05	0.000137	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	7.46e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GHRL—polycystic ovary syndrome	7.39e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PLAT—polycystic ovary syndrome	7.39e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	7.37e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GHRL—polycystic ovary syndrome	7.34e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FST—polycystic ovary syndrome	7.34e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PLAT—polycystic ovary syndrome	7.34e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	7.3e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	7.25e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF18—polycystic ovary syndrome	7.25e-05	0.000132	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	7.24e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RBP4—polycystic ovary syndrome	7.18e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PLAT—polycystic ovary syndrome	7.18e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GHRL—polycystic ovary syndrome	7.18e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LHB—polycystic ovary syndrome	7.16e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	7.15e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	7.15e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	7.15e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.12e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	7.12e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	7.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ATF1—polycystic ovary syndrome	7.05e-05	0.000128	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	7.04e-05	0.000128	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	7e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ATF1—polycystic ovary syndrome	7e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.92e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.88e-05	0.000125	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	6.86e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ATF1—polycystic ovary syndrome	6.85e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.85e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.83e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.79e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	6.78e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	6.77e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SCT—polycystic ovary syndrome	6.71e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—YAP1—polycystic ovary syndrome	6.71e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.68e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.65e-05	0.000121	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	6.64e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	6.63e-05	0.000121	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	6.62e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GAB1—polycystic ovary syndrome	6.62e-05	0.00012	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	6.55e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGFR—polycystic ovary syndrome	6.51e-05	0.000118	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.51e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—POMC—polycystic ovary syndrome	6.47e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGFR—polycystic ovary syndrome	6.46e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRL—polycystic ovary syndrome	6.45e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—POMC—polycystic ovary syndrome	6.42e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	6.4e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRL—polycystic ovary syndrome	6.4e-05	0.000117	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	6.35e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INSR—polycystic ovary syndrome	6.33e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGFR—polycystic ovary syndrome	6.33e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF18—polycystic ovary syndrome	6.29e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—POMC—polycystic ovary syndrome	6.29e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRL—polycystic ovary syndrome	6.27e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RBP4—polycystic ovary syndrome	6.24e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.22e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	6.21e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.17e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	6.14e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.12e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.07e-05	0.000111	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	6.05e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.04e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.01e-05	0.000109	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	5.98e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.95e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.92e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PGR—polycystic ovary syndrome	5.86e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	5.84e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—YAP1—polycystic ovary syndrome	5.82e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GAB1—polycystic ovary syndrome	5.74e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNAS—polycystic ovary syndrome	5.67e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	5.67e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	5.65e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	5.65e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNAS—polycystic ovary syndrome	5.63e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	5.57e-05	0.000101	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	5.52e-05	0.0001	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNAS—polycystic ovary syndrome	5.51e-05	0.0001	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INSR—polycystic ovary syndrome	5.49e-05	0.0001	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLAT—polycystic ovary syndrome	5.44e-05	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GHRL—polycystic ovary syndrome	5.44e-05	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.41e-05	9.84e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	5.4e-05	9.82e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.36e-05	9.77e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRG1—polycystic ovary syndrome	5.31e-05	9.66e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRG1—polycystic ovary syndrome	5.27e-05	9.59e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.25e-05	9.56e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.25e-05	9.55e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	5.23e-05	9.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	5.22e-05	9.5e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ATF1—polycystic ovary syndrome	5.19e-05	9.46e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRG1—polycystic ovary syndrome	5.16e-05	9.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.14e-05	9.35e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	5.09e-05	9.26e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	5.08e-05	9.24e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.07e-05	9.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.04e-05	9.18e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	4.96e-05	9.03e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	4.81e-05	8.75e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	4.81e-05	8.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGFR—polycystic ovary syndrome	4.79e-05	8.73e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	4.76e-05	8.67e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	4.75e-05	8.65e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	4.73e-05	8.62e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	4.73e-05	8.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	4.73e-05	8.61e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	4.66e-05	8.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.58e-05	8.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.55e-05	8.29e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IRS2—polycystic ovary syndrome	4.55e-05	8.27e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IRS2—polycystic ovary syndrome	4.51e-05	8.21e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	4.51e-05	8.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.51e-05	8.2e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—polycystic ovary syndrome	4.5e-05	8.19e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	4.49e-05	8.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	4.49e-05	8.17e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LEP—polycystic ovary syndrome	4.45e-05	8.1e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	4.42e-05	8.05e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IRS2—polycystic ovary syndrome	4.42e-05	8.04e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LEP—polycystic ovary syndrome	4.41e-05	8.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.4e-05	8.01e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.38e-05	7.97e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LEP—polycystic ovary syndrome	4.32e-05	7.87e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	4.31e-05	7.85e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.29e-05	7.81e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	4.28e-05	7.8e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	4.28e-05	7.79e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	4.26e-05	7.75e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.23e-05	7.7e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	4.18e-05	7.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	4.16e-05	7.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.14e-05	7.53e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	4.13e-05	7.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.13e-05	7.51e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	4.02e-05	7.32e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.98e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.98e-05	7.24e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IRS1—polycystic ovary syndrome	3.97e-05	7.22e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	3.97e-05	7.22e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	3.96e-05	7.21e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	3.94e-05	7.17e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	3.92e-05	7.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.91e-05	7.12e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	3.91e-05	7.11e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.86e-05	7.02e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—polycystic ovary syndrome	3.82e-05	6.96e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	3.82e-05	6.95e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INS—polycystic ovary syndrome	3.8e-05	6.92e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	3.79e-05	6.9e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	3.77e-05	6.86e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	3.71e-05	6.76e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	3.7e-05	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	3.69e-05	6.72e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—polycystic ovary syndrome	3.68e-05	6.69e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	3.67e-05	6.69e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	3.65e-05	6.64e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	3.64e-05	6.63e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	3.64e-05	6.63e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	3.64e-05	6.63e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.63e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.57e-05	6.5e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.57e-05	6.5e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.49e-05	6.35e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.46e-05	6.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.46e-05	6.29e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TH—polycystic ovary syndrome	3.43e-05	6.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.39e-05	6.18e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.39e-05	6.17e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.35e-05	6.09e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	3.33e-05	6.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.32e-05	6.04e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.28e-05	5.96e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.24e-05	5.91e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.15e-05	5.74e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.14e-05	5.72e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	3.13e-05	5.71e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.07e-05	5.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.92e-05	5.32e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.91e-05	5.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.89e-05	5.26e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	2.88e-05	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.84e-05	5.18e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.81e-05	5.12e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	2.81e-05	5.12e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.8e-05	5.1e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	2.8e-05	5.09e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	2.8e-05	5.09e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.79e-05	5.08e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.73e-05	4.97e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.71e-05	4.93e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.7e-05	4.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.7e-05	4.91e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.66e-05	4.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.59e-05	4.72e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	2.57e-05	4.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.57e-05	4.68e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.56e-05	4.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.54e-05	4.62e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.53e-05	4.6e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.45e-05	4.46e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.44e-05	4.45e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.43e-05	4.42e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.42e-05	4.4e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.4e-05	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.38e-05	4.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.38e-05	4.34e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	2.36e-05	4.29e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.35e-05	4.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.35e-05	4.28e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.33e-05	4.25e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.32e-05	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.23e-05	4.06e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.17e-05	3.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.07e-05	3.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.06e-05	3.75e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2e-05	3.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.91e-05	3.48e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.88e-05	3.43e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.88e-05	3.43e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.87e-05	3.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.8e-05	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.77e-05	3.22e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.76e-05	3.2e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.73e-05	3.15e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.72e-05	3.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.68e-05	3.06e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.66e-05	3.02e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.65e-05	3e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.61e-05	2.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.6e-05	2.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.54e-05	2.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.52e-05	2.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.42e-05	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.22e-05	2.23e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.15e-05	2.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.13e-05	2.06e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.13e-05	2.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.06e-05	1.93e-05	CbGpPWpGaD
